Worldwide prevalence of microbial agents’ coinfection among COVID‐19 patients: A comprehensive updated systematic review and meta‐analysis

Abstract

Background

To provide information about pathogens’ coinfection prevalence with SARS‐CoV‐2 could be a real help to save patients’ lives. This study aims to evaluate the pathogens’ coinfection prevalence among COVID‐19 patients.

Method

In order to find all of the relevant articles, we used systematic search approach. Research‐based databases including PubMed, Web of Science, Embase, and Scopus, without language restrictions, were searched to identify the relevant bacterial, fungal, and viral coinfections among COVID‐19 cases from December 1, 2019, to August 23, 2021. In order to dig deeper, other scientific repositories such as Medrxiv were probed.

Results

A total of 13,023 studies were found through systematic search. After thorough analysis, only 64 studies with 61,547 patients were included in the study. The most common causative agents of coinfection among COVID‐19 patients were bacteria (pooled prevalence: 20.97%; 95% CI: 15.95–26.46; I ²: 99.9%) and less frequent were virus coinfections (pooled prevalence: 12.58%; 95% CI: 7.31–18.96; I ²: 98.7%). The pooled prevalence of fungal coinfections was also 12.60% (95% CI: 7.84–17.36; I ²: 98.3%). Meta‐regression analysis showed that the age sample size and WHO geographic region did not influenced heterogeneity.

Conclusion

We identified a high prevalence of pathogenic microorganism coinfection among COVID‐19 patients. Because of this rate of coinfection empirical use of antibacterial, antifungal, and antiviral treatment are advisable specifically at the early stage of COVID‐19 infection. We also suggest running simultaneously diagnostic tests to identify other microbiological agents’ coinfection with SARS‐CoV‐2.

Prevalence of microbial coinfection in COVID‐19 patients is essential for clinicians. Systematic search andmeta‐analysis showed a high prevalence of pathogenic microorganisms, especially bacteria, among COVID‐19 patients.

1. INTRODUCTION

COVID‐19 was declared as the new respiratory pandemic in March 2020. ¹  Microbial pathogens coinfections always played an important role in increasing mortality and morbidity rate in pandemics. Their coinfection with SARS‐CoV‐2 is not an exception. While countries applied different measures to limit spread of the virus, new wave still striking and quickly mutate and gain new feature which has made it more dangerous than ever. ²

Viral, bacterial, and fungal coinfections alter the pathophysiology of disease, also the patient recovery outcome. ³ , ⁴ Respiratory viruses’ including hRV, hMPV, and RSV are associated with majority respiratory viral coinfection. ⁵ Also, immunosuppression and immunodeficiency condition such as HIV infection could effect on COVID‐19 disease. ⁶

Fungal infection plays a major threat to patient's life in intensive care units. ⁷ Fungal coinfections such as Aspergillus and Candida species could increase mortality rate, especially in critically ill patients. ⁸ One of the great challenges for clinicians is their detection. Fungal coinfection remained undetectable even after the death of the patients. ⁹ Similar clinical and radiological features between SARS‐CoV‐2 and fungal pathogens are the other difficulties that healthcare providers have to dealt with. ¹⁰

Among microbiological coinfections, bacterial pathogens are considered more important agents based on their previous record viral outbreaks and pandemics. ¹¹ It also was reported people with bacterial coinfection showed high number of mortality. Critical ill patients showed greater percentage of coinfection compared to hospitalized patients. ¹² One of the main importance of assessing bacterial coinfection prevalence is about applying empirical antibiotic treatment, in SARS‐CoV‐2 patients. Extensive use of antibiotics could lead to several such as antibacterial resistance. ¹³ , ¹⁴ Some of the respiratory bacterial pathogen such as pneumococcal, staphylococcal, and Klebsiella with SARS‐CoV‐2 have common clinical manifestation; therefore, antibiotics treatment would be more difficult than regular situation. ¹⁵  This study aims to evaluate the microbiological coinfection prevalence among COVID‐19 patients.

2. MATERIALS AND METHODS

We performed our research based on PRISMA guideline studies ¹⁶ we registered our article search protocol in the International Prospective Register of Systemic Reviews with CRD42021277142. We used related unique keywords to conduct our search strategy and retrieving all of the related articles.

2.1. Method of literature search

We explored the online scientific repositories without setting any language barrier. PubMed, Web of Science, Embase, and Scopus were probed to find the relevant articles about pathogens’ coinfection prevalence in COVID‐19‐infected persons between December 1, 2019, and August 23, 2021. Other knowledge‐based databases such as Medrxiv and SSRN were also used to gather the off‐the‐record articles. We chose the keywords in this article based on MeSH Terms. The PICOTS in our study are available in Appendix 1.

To find other off‐the‐record publication, we probed Google Scholar. A microbiologist was asked to identify and validate the related articles. Simultaneously, we hand‐searched our articles library to gather other relevant studies. We imported all of the gathered data to Endnote X6. The duplicated articles were removed. We scanned the remained studies in three distinguished steps. Firstly, we probed the articles based on their titles. Afterward, the abstract of the screened articles were reviewed, and the full text of the relevant ones were collected. We conducted the study selection procedure based on blinding and task separation. The mentioned procedure was done by two independent reviewers simultaneously. In case of any disagreement between reviewers (Inter‐rater discrepancies), another rater were asked to resolve the problem. The kappa coefficient for agreement between two raters was equal to 93%.

2.2. Inclusion and exclusion criteria

All the related studies including cross‐sectional, case series, and cohort studies evaluating the prevalence of viral, bacterial, and fungal coinfections among COVID‐19 cases were gathered. The case series and case report articles with <10 sample sizes did not reviewed in this study. We excluded the other types of articles including clinical trials, reviews, and case‐control articles.

2.3. Data extraction

We extracted the necessary data from all of the studies including authors’ name, study year, country, study design, sample size, gender, age, number, and type of coinfections.

2.4. Variable definition

Bacteria type were classified based on transmission way and clinical signs. Countries were categorized based on the latest WHO definition that includes the following six regions: Regional Office for Africa (AFRO), Regional Office for the Americas (AMRO), Regional Office for the Eastern Mediterranean (EMRO), Regional Office for Europe (EURO), Regional Office for South‐East Asia (SEARO), and the Regional Office for the Western Pacific (WPRO).

2.5. Quality assessment

Newcastle‐Ottawa Scale ¹⁷ evaluated the quality of the finalized studies. We assessed the studies based on three selection steps of this scale: 1‐Selection 2‐Confounder, and 3‐Exposure. Two independent reviewers examined the articles based on the Newcastle‐Ottawa criteria (RP and SS), and the total score for each study in the three steps was calculated. Afterward, the selected studies were categorized in the following groups: very good, good, satisfactory, and unsatisfactory studies. ¹⁸

2.6. Statistical analysis

All statistical tests in this study were performed with Stata 14.0. Just like previous researches, ¹⁸ , ¹⁹ , ²⁰ , ²¹ the sample size, the coinfection prevalence in COVID‐19 cases, and the coinfection causative agent's types and species were extracted. We applied Cochran's Q test to determine the heterogeneity. We also quantified it with the I ² index. I ² values above 0.7 were determined as high heterogeneity based on the Higgins classification approach. ²²  Metaprop package were used to calculate the pooled prevalence with 95% confidence interval. Random‐effects model was applied to estimate the pooled prevalence. This package applies double arcsine transformations to stabilize the variance in the meta‐analyses. The effect of sample size, age, and WHO geographic regions on the studies heterogeneity were analyzed by meta‐regression analysis. Publication bias evaluated by “metabias” command. In case of any publication bias, we adjusted the prevalence rate with “metatrim” command applying trim‐and‐fill approach. Statistical significance was considered 0.05.

3. RESULT

We collected 13,241 articles probing the mentioned databases. We also found 151 articles through other resources. By removing the duplicated articles, 8838 articles remained. The remained articles were screened in three distinguished steps. First, we exclude the 6542 studies by analyzing their titles. Then After reviewing the abstracts, 1924 studies were removed from the library. In the third step, the full text of the 372 remained articles was comprehensively studied, and we exclude the 308 studies. A total of 64 studies ³ , ⁵ , ¹⁸ , ²³ , ²⁴ , ²⁵ , ²⁶ , ²⁷ , ²⁸ , ²⁹ , ³⁰ , ³¹ , ³² , ³³ , ³⁴ , ³⁵ , ³⁶ , ³⁷ , ³⁸ , ³⁹ , ⁴⁰ , ⁴¹ , ⁴² , ⁴³ , ⁴⁴ , ⁴⁵ , ⁴⁶ , ⁴⁷ , ⁴⁸ , ⁴⁹ , ⁵⁰ , ⁵¹ , ⁵² , ⁵³ , ⁵⁴ , ⁵⁵ , ⁵⁶ , ⁵⁷ , ⁵⁸ , ⁵⁹ , ⁶⁰ , ⁶¹ , ⁶² , ⁶³ , ⁶⁴ , ⁶⁵ , ⁶⁶ , ⁶⁷ , ⁶⁸ , ⁶⁹ , ⁷⁰ , ⁷¹ , ⁷² , ⁷³ , ⁷⁴ , ⁷⁵ , ⁷⁶ , ⁷⁷ , ⁷⁸ , ⁷⁹ with 61,547 total sample size were included in our study. Selection process flow chart is available in Figure 1, and Table 1 shows the studies’ characteristics. The highest studies number belonged to Western Pacific (25 studies) area, Southeast Asia (three studies), and Eastern Mediterranean Region (three studies) was the lowest one. All the included studies were published during 2020. The minimum and maximum age range of the subjects was for Wu et al. ²⁸ article had the lowest age ranges (mean age = 6 years old) and Wang et al. ⁶⁵  study (mean age = 73 years old), and D’Onofrio et al. ⁵⁶  study (mean age = 73 years old) reported the highest age range. Twenty‐eight (43.75%) of studies were case series. There were also 29 (45.31%) cohort and 7 (10.94%) cross‐sectional.

FIGURE 1.

Study selection process based on PRISMA flow diagram

TABLE 1.

Characteristics of the studies included in this meta‐analysis

Author	Country	Design	Publication year	Mean age	Sample size	Viral coinfections prevalence (95% CI)	Bacterial coinfections prevalence (95% CI)	Fungal coinfections prevalence (95% CI)
Zhu et al. 22	China	Case series	2020	51	257	31.52 (25.89–37.58)	91.83 (87.78–94.87)	23.35 (18.31–29)
Zheng et al. 75	China	Case series	2020	30.6	1001	0.40 (0.11–1.02)	NA	NA
Agrifoglio et al. 76	Spain	Cohort	2020	58.7	139	NA	NA	16.55 (10.79–23.79)
Blasco et al. 58	Spain	Case series	2020	64	183	0.55 (0.01–3.01)	1.64 (0.34–4.72)	NA
Contou et al. 56	France	Case series	2020	61	92	14.13 (7.74–22.95)	95.65 (89.24–98.8)	NA
Sarinoglu et al. 34	Turkey	Cross‐sectional	2020	–	30	NA	6.67 (0.82–22.07)	NA
Chauhdary et al. 57	Brunei	Case series	2020	–	141	NA	4.53 (3.01–6.52)	NA
Chen et al. 42	China	Case series	2020	52.5	326	6.13 (3.79–9.32)	NA	NA
Chen et al. 59	China	Case series	2020	51	123	12.2 (6.99–19.32)	NA	NA
Cheng et al. 42	China	Cohort	2020	36	62	NA	40.32 (28.05–53.55)	NA
Chowdhary et al. 77	India	Cross‐sectional	2020		596	NA	NA	4.53 (3.01–6.52)
D’Onofrio et al. 55	Belgium	Cohort	2020	73	110	NA	2.73 (0.57–7.76)	NA
Luna et al. 60	Brazil	Case series	2020		115	11.3 (6.16–18.55)	NA	NA
Ding et al. 61	China	Case series	2020	50.2	115	4.35 (1.43–9.85)	NA	NA
Ebrahim 62	Saudi Arabia	Case series	2020	44	99	0 (0–3.66)	NA	NA
Fu et al. 54	China	Cohort	2020		101	NA	4.95 (1.63–11.18)	NA
Garcia‐Vidal et al. 53	Spain	Cohort	2020	62	989	0.61 (0.22–1.32)	2.93 (1.97–4.18)	NA
Gayam et al. 52	USA	Cohort	2020	57	350	NA	1.71 (0.63–3.69)	NA
Gupta et al. 50	India	Cohort	2020	36	1073	NA	2.05 (1.29–3.09)	NA
Hashemi et al. 63	Iran	Case series	2020		105	21.9 (14.42–31.03)	NA	NA
Hazra et al. 49	USA	Cross‐sectional	2020		459	3.7 (2.17–5.86)	0.00 (0.00–0.80)	NA
Hirotsu et al. 48	Japan	Cross‐sectional	2020		40	NA	0.00 (0.00–8.81)	NA
Hughes et al. 47	UK	Case series	2020	69.5	836	0.00 (0.00–0.44)	3.23 (2.14–4.66)	0.36 (0.07–1.05)
Intra et al. 46	Italy	Cohort	2020		61	NA	68.85 (55.71–80.1)	68.85 (55.71–80.1)
Jiang et al. 64	China	Case series	2020		161	47.2 (39.3–55.22)	NA	NA
Karami et al. 45	Netherlands	Cohort	2020	70	925	NA	0.86 (0.37–1.7)	NA
Kim et al. 5	USA	Cross‐sectional	2020	46.9	116	21.55 (14.46–30.15)	0.00 (0.00–3.13)	NA
Kimmig et al. 44	USA	Cohort	2020	46.9	111	NA	37.84 (28.8–47.54)	NA
Leuzinger et al. 65	Switzerland	Case series	2020	49	825	12.97 (10.75–15.46)	NA	NA
Li et al. 27	China	Cohort	2020	66.2	1495	NA	20.6 (18.58–22.74)	NA
Li et al. 18	China	Case series	2020	57	32	15.63 (5.28–32.79)	31.25 (16.12–50.01)	NA
Lin et al. 66	China	Case series	2020		92	6.52 (2.43–13.66)	NA	NA
Lin et al. 67	China	Case series	2020	45	133	12.78 (7.63–19.67)	NA	NA
Liu et al. 43	China	Case series	2020	46.5	20	NA	20 (5.73–43.66)	NA
Lv et al. 42	China	Cohort	2020	62	354	0.28 (0.01–1.56)	14.12 (10.67–18.19)	NA
Ma et al. 41	China	Case series	2020	45.5	250	8.8 (5.6–13.02)	9.6 (6.25–13.95)	NA
Ma et al. 68	China	Cross‐sectional	2020	67	93	49.46 (38.93–60.03)	NA	NA
Massey et al. 40	USA	Case series	2020	62.3	790	34.18 (30.87–37.6)	55.44 (51.9–58.95)	NA
Motta et al. 39	Multi‐place a	Cohort	2020		69	1.45 (0.04–7.81)	7.25 (2.39–16.11)	NA
Neto et al. 51	USA	Cohort	2020	66	242	NA	19.01 (14.27–24.53)	NA
Verroken et al. 28	Netherlands	Cohort	2020		32	NA	18.75 (7.21–36.44)	NA
Nori et al. 38	USA	Cohort	2020	62	152	NA	44.08 (36.04–52.35)	NA
Nowak et al. 69	USA	Case series	2020	60.2	408	20.34 (16.54–24.58)	NA	NA
Pandey et al. 29	India	Cross‐sectional	2020		120	NA	13.33 (7.82–20.75)	NA
Porretta et al. 37	Italy	Cohort	2020	67.4	331	NA	9.67 (6.71–13.37)	NA
Ripa et al. 36	Italy	Cohort	2020	64	731	NA	7.25 (5.48–9.38)	NA
Rothe et al. 35	Germany	Cohort	2020	63.5	140	NA	76.43 (68.52–83.19)	NA
Segrelles‐Calvo et al. 78	Spain	Cohort	2020	59.6	215	NA	NA	29.3 (23.31–35.88)
Sepulveda et al. 33	USA	Cohort	2020		28011	NA	3.8 (3.58–4.03)	NA
Sharifipour et al. 3	Iran	Case series	2020	67.1	19	NA	100 (82.35–100)	NA
Sharov et al. 32	Russia	Case series	2020		147	59.86 (51.47–67.85)	75.51 (67.74–82.22)	NA
Sy et al. 31	Philippine	Cohort	2020	44.21	12513	NA	0.90 (0.74–1.08)	NA
Tadolini M et al. 30	Global	Cohort	2020	48	49	NA	85.71 (72.76–94.06)	NA
Teotonio et al. 70	Brazil	Case series	2020	44.55	112	38.39 (29.36–48.06)	NA	NA
Vaughn et al. 71	USA	Cohort	2020	64.7	1705	0.53 (0.24–1.00)	NA	NA
Wang J et al. 64	China	Case series	2020	73	104	NA	NA	7.69 (3.38–14.6)
Weissberg et al. 72	Switzerland	Cohort	2020	49	11	9.09 (0.23–41.28)	NA	NA
Wu et al. 27	China	Case series	2020	6	74	13.51 (6.68–23.45)	47.3 (35.57–59.25)	NA
Youngs et al. 26	UK	Cohort	2020	59	36	NA	30.56 (16.35–48.11)	NA
Yu et al. 25	Sweden	Cohort	2020		2240	NA	10.09 (8.87–11.41)	NA
Yu et al. 73	China	Cohort	2020	57	67	10.45 (4.3–20.35)	NA	NA
Yue et al. 74	China	Case series	2020		307	49.84 (44.11–55.57)	NA	NA
Zha et al. 24	China	Cohort	2020	57	874	NA	2.52 (1.58–3.79)	NA
Zhang et al. 23	China	Case series	2020	64.76	38	15.79 (6.02–31.25)	57.89 (40.82–73.69)	10.53 (2.94–24.8)

Abbreviation: CI, confidence interval.

^a Belgium, Brazil, France, Italy, Russia, Singapore, Spain, and Switzerland.

3.1. Pooled prevalence of coinfections in COVID‐19 patients

Table 1 exhibits all included studies coinfection prevalence. Figure 2 shows the coinfection prevalence forest plot. Minimum and maximum coinfection prevalence were in Hazra et al. study ⁵⁰ (prevalence: 0.00%; 95%CI: 0.00–0.80) from the USA and Sharif pour et al. article ³ (prevalence: 100.00%:95% CI: 82.35–100.00) from Iran which were resulted from random‐effects model approach (available in Figure 2) respectively. Pooled estimate of coinfection prevalence was 16.98% (95% CI: 13.62–20.62). Therefore, from every 1000 COVID‐19‐infected person, 136 to 20.6 individuals infected with another types of pathogens have coinfections.

FIGURE 2.

Prevalence of all‐type coinfections in patients with COVID‐19 Forest plot based on a random‐effects model. Each study identifies distinguished by their author (year) and countries. Each line segment's midpoint shows the prevalence estimate, length of line segment indicates 95% confidence interval (CI) in each study, and diamond mark illustrates the pooled estimate

3.2. Pooled prevalence of coinfections based on different subgroups

Pooled coinfection prevalence based on coinfections pathogens subtypes and regions are listed in Figure 3. Supplements 1–3 show the different pathogens species (bacterial, fungal, and viral coinfections) coinfection prevalence forest plot. The most prevalent subtype was bacteria (pooled prevalence: 20.97%; 95% CI: 15.95−26.46; I ²: 99.9%), and viral coinfections were the less frequent ones (pooled prevalence: 12.58%: 95% CI: 7.31–18.96; I ²: 98.7%). The pooled prevalence of fungal coinfections was 12.60% (95% CI: 7.84–17.36; I ²: 98.3%).

FIGURE 3.

Pooled prevalence with 95% confidence interval [CI] and heterogeneity indexes of coinfections in COVID‐19 patients based on type of the coinfections and different regional places. The diamond mark illustrates the pooled prevalence and the length of the diamond indicates the 95% CI

Analysis showed that EMRO were the most coinfection regions 36.92% (95% CI: 0.00–90.72; I ²: 0%). least coinfections pooled prevalence were resulted from SEARO regions 5.34% (95% CI: 1.74–10.66; I ²: 0%): EURO, WPRO, and AMRO pooled prevalence are accessible in Figure 3.

3.3. Heterogeneity and meta‐regression

Heterogeneity results are available in Table 2. Cochran's Q test showed the included studies had high heterogeneity (p < 0.001). The I ² index for total coinfections and pathogen subtypes were up to 90%. Meta‐regression analysis showed the age (Coefficient: −0. × 10⁻³; p: 0.777), sample size (Coefficient: −0.1 × 10⁻⁴; p: 0.192) and region (based WHO regional office) size (Coefficient: −0.034; p: 0.214) possess no significant effect on the studies heterogeneity (Figure 4A,B).

TABLE 2.

The univariate meta‐regression analysis on the hertogenisity of the determinants in included studies for coinfections in COVID‐19 patients

Variables	Coefficient	95% CI	p‐value
Age (year)	−0.7 × 10−3	−5.6 × 10−3 to 4.2 × 10−3	0.777
WHO region (score)	−0.034	−0.087 to 0.019	0.214
Sample size (Number)	−0.1 × 10−4	−0.2 × 10−4 to 0.5 × 10−5	0.192

Coding of WHO region: 1 = EMRO; 2 = EURO; 3 = AMRO; 4 = WPRO; SEARO = 5.

Abbreviation: CI, confidence interval.

FIGURE 4.

Association between prevalence of age (A) and sample size (B) with prevalence of coinfections by means of meta‐regression. The size of circles indicates the precision of each study. There is no significant association with respect to the prevalence of coinfections with age sample size

3.4. Publication bias

Egger's test results (coefficient: −0.41, p: 0.899) exhibited that there was not any significant publication bias in this meta‐analysis.

4. DISCUSSION

Our result elucidated that overall coinfection prevalence was 16.98. The lowest coinfection prevalence was reported in the USA and the highest level of coinfection was in Iran. As we expected between pathogenic microorganisms, bacterial agents were the most frequent and viral coinfection had the lowest coinfection rate in COVID‐19 patients. We also found out that EMRO region had the most prevalence of coinfection and compare to that SEARO region was the lowest coinfection area.

Respiratory viruses transmitted between different species and manifests clinical features similar to COVID‐19, which is a potential threat for COVID‐19‐infected cases. ⁸⁰ , ⁸¹ A systematic review and meta‐analysis reported that influenza type A, rhinovirus, and non‐SARS‐CoV‐2 coronaviruses are the most frequent viruses among coinfected patients ⁸² Another systematic review showed that 11.6% of SARS‐CoV‐2 patients had viral coinfection. ⁸³  Malekifar et al. ⁸⁴ showed the prevalence of 12.58% viral coinfection among COVID‐19 patients.

Compare to other systematic review studies focused on coinfection question, we found a higher coinfection rate. Our result showed that 20.97%; of patients were infected with at least one bacterial pathogens which is much higher than other studies reported 7%–8% of coinfection prevalence among COVID‐19 patients. ⁸¹

The rate of bacterial coinfection prevalence among critically ill patients is one of the important issues during pandemic, which related to higher comorbidity. A meta‐analysis study showed 8.1% of coinfection among critically ill patients compared to 5.9% hospitalized ones. ⁸⁵ Soltani et al. ⁸⁶ showed the prevalence of 20.97 bacterial co‐infection in COVID‐19‐infected cases. Another important aspect of bacterial co‐infection prevalence is about empirical bacterial treatment (52). Several research articles concluded that the increasing antibiotic prescription among COVID‐19 cases would lead to antibiotic resistance in the next few years. ⁸⁷  More than 70% of COVID‐19 cases received some kind of antibiotics agents including fluoroquinolones and third‐generation cephalosporins. ⁸⁵

We identified 12.60% of fungal coinfection among COVID‐19‐infected individuals, which is also higher than other studies focused on similar question. A systematic review and meta‐analysis showed the prevalence of fungal coinfections and super infection, 4% and 8% respectively ⁸² another study reported of both the fungal coinfection and super infection 4%. Like other types of pathogens, which mentioned before fungal pathogens have similar laboratory manifestation with other respiratory viruses. This problem could be detrimental when it comes to patients’ clinical care and treatment. ¹⁵ For example, there were negative serology and cell culture test for Aspergillus coinfection in COVID‐19 patients. ⁸⁸ Candida albicans is the most frequent candida species among COVID‐19 patients with critical conditions. ⁸⁹ Aspergillus is the other frequent invasive fungal pathogens among the patients. ⁹⁰

4.1. Strength, limitation, and suggestions for future studies

We faced some limitation in our study. One: we could not perform gender‐specific estimation because of primary studies little data;

Two: pooled prevalence in this study were analyzed based on WHO regional office; therefore, we wanted to conduct the spatial analysis in geographic regions, ⁹¹ , ⁹² , ⁹³ , ⁹⁴ but because of infrequent studies number, we would not sure about robust results. Performing a through‐full study probe search and estimating the different coinfections species pooled prevalence were our study's strengths. Because of increasing rate of pathogens coinfection prevalence in COVID‐19 patients, we suggest that a world registry will be developed in order to screen the pattern of coinfections. ⁹⁵ , ⁹⁶

5. CONCLUSION

In conclusion, we identified a higher level of pathogenic microorganism coinfection among COVID‐19 patients. Because of this rate of coinfection, we support the empirical use of antibacterial, antifungal, and antiviral treatment specifically at the onset of the COVID‐19 infection. We also encourage clinician to run diagnostic test for other pathogens simultaneously with SARS‐CoV‐2, which is important to properly patient's treatment.

CONFLICTS OF INTEREST

The authors report no conflicts of interest in this work.

AUTHOR CONTRIBUTIONS

Saber Soltani conceptualized and designed the review, Saber Soltani, Reza Pakzad, Pooneh Malekifar, Zainab Shateri, Milad Zandi and Abbas Farahani contributed to interpretation of data for the work, wrote the article, and final approval of the version to be published. Sara Akhavan Rezayat, Maral Soleymani, Mohammad Reza Karimi, and Seyed Esmaeil Ahmadi collected data and wrote the article. Ramin Shahbahrami, Iraj Pakzad, Mina Mobini Kesheh, Parastoo Hosseini, and Fatemeh Abdi supervised the collection of the data and wrote the article. All authors reviewed and approved the article.

6. ETHICAL APPROVAL

Not applicable.

Supporting information

Fig S1

Fig S2

Fig S3

APPENDIX 1.

Population: COVID‐19 patients.

Intervention: None.

Comparison: None.

Outcome: Prevalence of coinfections.

Time: from December 1, 2019 until August 23, 2021.

Study design: Observational study.

The search strategy is described in Appendix 1 that is applied based on PICOTS for MEDLINE (MeSH) and then used in other databases.1

BOX 1. Search strategy based on PICO for MEDLINE (MeSH, Medical Subject Headings).

1. COVID‐19 [text word] OR COVID‐19 [Mesh term]

2. Coronavirus [text word] OR Coronavirus [Mesh term]

3. SARS‐CoV‐2 infection [text word] OR SARS‐CoV‐2 infection [Mesh term]

4. 1 OR 2 OR 3

5. Prevalence [text word] OR Prevalence [Mesh term]

6. Frequency [text word] OR Frequency [Mesh term]

7. Incidence [text word] OR Incidence [Mesh term]

8. 5 OR 6 OR 7

9. Coinfection [text word] OR Coinfection [Mesh term]

10. Mixed Infection [text word] OR Mixed Infection [Mesh term]

11. Polymicrobial Coinfection [text word] OR Polymicrobial Coinfection [Mesh term]

12. Bacterial Coinfection [text word] OR Bacterial Coinfection [Mesh term]

13. Viral Coinfection [text word] OR Viral Coinfection [Mesh term]

14. Fungal Coinfection [text word] OR Viral Coinfection [Mesh term]

15. 9 OR 10 OR 11 OR 12 OR 13 OR 14

16: 4 AND 8 AND 15

Pakzad R, Malekifar P, Shateri Z, et al. Worldwide prevalence of microbial agents’ coinfection among COVID‐19 patients: A comprehensive updated systematic review and meta‐analysis. J Clin Lab Anal.2022;36:e24151. doi: 10.1002/jcla.24151

DATA AVAILABILITY STATEMENT

All data associated with this article are inclusive in this article.